Skip to main content

Advertisement

Table 2 Baseline characteristics of participants and non-participants

From: Randomized controlled trial of the effects of high intensity and low-to-moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the Resistance and Endurance exercise After ChemoTherapy (REACT) study

Characteristics HI LMI WLC Non-participants
n = 91 n = 95 n = 91 n = 479
Sociodemographic
Age, mean (SD) years 54 (11.0) 53 (11.3) 54 (10.9) 55 (11.6)
Sex, n (%) male a 18 (20) 17 (18) 20 (22) 77 (16)
Married/living together, n (%) yes 73 (80) f 87 (92) f 72 (79) f  
Education, n (%) b
 Low 19 (21) 12 (13) 16 (18)  
 Intermediate 37 (41) 43 (46) 42 (46)  
 High 34 (38) 38 (40) 33 (36)  
Being employed, n (%)
 Employed 54 (59) 56 (58) 57 (63)  
 Not employed 25 (28) 22 (23) 19 (21)  
 Retirement 12 (13) 17 (18) 15 (17)  
Smoking, n (%) yes c 7 (8) 5 (5) 5 (6)  
Comorbidity, n (%) yes 12 (13) 8 (8) 10 (11)  
Sport history, n (%) yes d 45 (50) 61 (65) 49 (54)  
Exercise during chemotherapy, n (%) yes b 21 (23) 21 (22) 10 (11)  
Clinical
Diagnosis, n (%) e
 Breast 62 (68) 62 (65) 57 (63) 309 (65)
 Colon 15 (17) 19 (20) 15 (17) 85 (18)
 Ovarian 4 (4) 3 (3) 5 (6) 23 (5)
 Lymphoma 9 (10) 9 (9) 8 (9) 47 (10)
 Cervix 0 (0) 2 (2) 2 (2) 12 (3)
 Testis 1 (1) 0 (0) 4 (4) 4 (1)
Stage of disease, n (%)
 Stage I–II 68 (75) 57 (60) 62 (68)  
 Stage II–IV 23 (25) 38 (40) 29 (32)  
Type of treatment, n (%) yes
 Surgery 83 (91) 87 (92) 80 (88)  
 Radiation therapy 46 (51) 41 (43) 48 (53)  
 Surgery + radiation therapy 41 (45) 39 (41) 46 (51)  
 Immunotherapy 16 (18) 25 (26) 18 (20)  
 Hormonal therapy 45 (50) 40 (42) 43 (47)  
Type of chemotherapy, n (%)
 TAC 39 (43) 33 (34) 31 (34)  
 FEC 7 (8) 7 (7) 5 (6)  
 TAC/FEC combinations 15 (17) 21 (22) 17 (19)  
 Capecitabine and oxaliplatin 8 (9) 11 (12) 7 (8)  
 Oxaliplatin combinations 7 (8) 8 (8) 7 (8)  
 Carboplatin and paclitaxel 4 (4) 4 (4) 10 (11)  
 CHOP 5 (6) 6 (6) 7 (8)  
 ABVD 4 (4) 2 (2) 2 (2)  
 Cisplatin 0 2 (2) 1 (1)  
 BEP 1 (1) 0 3 (3)  
 Other 1 (1) 1 (1) 1 (1)  
  1. HI, High intensity; LMI, Low-to-moderate intensity; WLC, Wait list control; FEC, Fluorouracil, epirubicin, cyclophosphamide; TAC, Taxotere, adriamycin, cyclophosphamide; CHOP, Cyclophosphamide, doxorubicin, vincristine, prednisone; ABVD, Doxorubicin, bleomycin, vinblastine, dacarbazine; BEP, Bleomycin, etoposide, cisplatin
  2. a n-4 (non-participants)
  3. b n-3
  4. c n-4
  5. d n-1
  6. e n-1 (non-participants)
  7. f P <0.05